NO924321L - Synergistiske terapeutiske blandinger og fremgangsmaater - Google Patents

Synergistiske terapeutiske blandinger og fremgangsmaater

Info

Publication number
NO924321L
NO924321L NO92924321A NO924321A NO924321L NO 924321 L NO924321 L NO 924321L NO 92924321 A NO92924321 A NO 92924321A NO 924321 A NO924321 A NO 924321A NO 924321 L NO924321 L NO 924321L
Authority
NO
Norway
Prior art keywords
mammal
synergistic
angiotensin
blood pressure
heart failure
Prior art date
Application number
NO92924321A
Other languages
English (en)
Norwegian (no)
Other versions
NO924321D0 (no
Inventor
Anthony Andrea Fossa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO924321(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO924321D0 publication Critical patent/NO924321D0/no
Publication of NO924321L publication Critical patent/NO924321L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO92924321A 1990-05-11 1992-11-10 Synergistiske terapeutiske blandinger og fremgangsmaater NO924321L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11
PCT/US1991/002733 WO1991017771A1 (en) 1990-05-11 1991-04-22 Synergistic therapeutic compositions and methods

Publications (2)

Publication Number Publication Date
NO924321D0 NO924321D0 (no) 1992-11-10
NO924321L true NO924321L (no) 1993-01-08

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924321A NO924321L (no) 1990-05-11 1992-11-10 Synergistiske terapeutiske blandinger og fremgangsmaater

Country Status (34)

Country Link
US (2) US6716875B1 (is)
EP (1) EP0527879B1 (is)
JP (2) JPH0729938B2 (is)
KR (1) KR970005839B1 (is)
CN (7) CN1824315B (is)
AP (1) AP240A (is)
AT (1) ATE148632T1 (is)
AU (1) AU653724B2 (is)
BG (1) BG61831B1 (is)
BR (1) BR9106438A (is)
CA (1) CA2081564C (is)
DE (1) DE69124598T2 (is)
DK (1) DK0527879T3 (is)
EG (1) EG19648A (is)
ES (1) ES2097208T3 (is)
GR (1) GR3022997T3 (is)
GT (1) GT199100032A (is)
HK (1) HK1094148A1 (is)
HU (1) HU227346B1 (is)
IE (1) IE911592A1 (is)
IL (1) IL98055A (is)
IS (1) IS2042B (is)
MA (1) MA22150A1 (is)
MY (1) MY114347A (is)
NO (1) NO924321L (is)
NZ (1) NZ238118A (is)
PE (1) PE30891A1 (is)
PT (1) PT97615B (is)
RO (1) RO115786B1 (is)
RU (1) RU2147875C1 (is)
TW (1) TW203553B (is)
WO (1) WO1991017771A1 (is)
YU (1) YU49094B (is)
ZA (1) ZA913539B (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147875C1 (ru) * 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
ATE220333T1 (de) 1996-04-05 2002-07-15 Takeda Chemical Industries Ltd Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
CA2257946A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
BR9814422A (pt) * 1997-12-23 2000-10-10 Warner Lambert Co Combinações de inibidor de ace - inibidor de mmp
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ATE551052T1 (de) * 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
RU2147875C1 (ru) * 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего

Also Published As

Publication number Publication date
PE30891A1 (es) 1991-11-27
IE911592A1 (en) 1991-11-20
AP9100258A0 (en) 1991-07-31
JPH05505618A (ja) 1993-08-19
CN1915428A (zh) 2007-02-21
BG97068A (bg) 1993-12-24
CN1824315B (zh) 2011-01-12
IL98055A (en) 1996-10-31
EG19648A (en) 1995-09-30
CN101156949A (zh) 2008-04-09
CN1065140C (zh) 2001-05-02
MY114347A (en) 2002-10-31
PT97615A (pt) 1992-03-31
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
HUT62804A (en) 1993-06-28
NO924321D0 (no) 1992-11-10
HU9203522D0 (en) 1993-01-28
CN1056426A (zh) 1991-11-27
DK0527879T3 (da) 1997-07-14
WO1991017771A1 (en) 1991-11-28
MA22150A1 (fr) 1991-12-31
RU2147875C1 (ru) 2000-04-27
HK1094148A1 (en) 2007-03-23
ZA913539B (en) 1992-12-30
YU49094B (sh) 2003-12-31
JP2635291B2 (ja) 1997-07-30
HU227346B1 (en) 2011-04-28
IL98055A0 (en) 1992-06-21
NZ238118A (en) 1997-06-24
US6716875B1 (en) 2004-04-06
CN1307901A (zh) 2001-08-15
JPH0729938B2 (ja) 1995-04-05
CN100358578C (zh) 2008-01-02
IS2042B (is) 2005-09-15
ATE148632T1 (de) 1997-02-15
CN1879884A (zh) 2006-12-20
AU653724B2 (en) 1994-10-13
EP0527879B1 (en) 1997-02-05
AP240A (en) 1993-02-18
JPH0748280A (ja) 1995-02-21
PT97615B (pt) 1998-08-31
CN1502370A (zh) 2004-06-09
US6900234B1 (en) 2005-05-31
YU81991A (sh) 1994-06-24
GT199100032A (es) 1992-10-31
IS3703A7 (is) 1991-11-12
AU7859191A (en) 1991-12-10
CA2081564A1 (en) 1991-11-12
ES2097208T3 (es) 1997-04-01
GR3022997T3 (en) 1997-07-30
DE69124598D1 (de) 1997-03-20
BR9106438A (pt) 1993-05-18
DE69124598T2 (de) 1997-05-28
BG61831B1 (bg) 1998-07-31
TW203553B (is) 1993-04-11
EP0527879A1 (en) 1993-02-24
RO115786B1 (ro) 2000-06-30
KR970005839B1 (ko) 1997-04-21

Similar Documents

Publication Publication Date Title
NO924321L (no) Synergistiske terapeutiske blandinger og fremgangsmaater
RU92016534A (ru) Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта
NO923130L (no) Behandling av kongestiv hjertesvikt
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
WO2003057225A3 (en) Phosphate transport inhibitors
NO20056252L (no) Terapeutiske og profylaktiske metoder for neuromuskulaere lidelser
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
AU3664401A (en) Platelet adp receptor inhibitors
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
WO2001062272A3 (en) Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
EP1059100A3 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
Gavras Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heart.
EP0981352B8 (en) Use of aplidine for the treatment of cardiovascular diseases
WO1992019211A3 (en) Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
HUP9801593A2 (hu) Benazeprilt vagy benazeprilátot és valzartánt tartalmazó kombinált gyógyszerkészítmények és azok alkalmazása
WO2001004116A3 (en) Neurotrophic pyrrolidines and piperidines, and related compositions containing them
WO1993020839A3 (en) Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
NO961333L (no) Nye pyrazolderivater som angiotensin-II-antagonister
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
AU706660B2 (en) Use of certain angiotensin II type I receptor antagonists for dyspeptic symptons in mammals including man